Profile data is unavailable for this security.
About the company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
- Revenue in USD (TTM)0.00
- Net income in USD-152.63m
- Incorporated2007
- Employees142.00
- LocationKura Oncology Inc12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 500-8800
- Fax+1 (302) 655-5049
- Websitehttps://www.kuraoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.26bn | 267.00 | -- | -- | -- | 2.85 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Novocure Ltd | 509.34m | -207.04m | 1.27bn | 1.45k | -- | 3.49 | -- | 2.49 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Tilray Brands Inc | 743.25m | -351.95m | 1.33bn | 1.60k | -- | 0.3964 | -- | 1.79 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Arcus Biosciences Inc | 117.00m | -307.00m | 1.33bn | 577.00 | -- | 2.40 | -- | 11.40 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.34bn | 155.00 | -- | 3.87 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.35bn | 147.00 | -- | 3.69 | -- | 65.15 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.36bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.38bn | 642.00 | 79.93 | 3.11 | 17.89 | 2.83 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
Kura Oncology Inc | 0.00 | -152.63m | 1.39bn | 142.00 | -- | 3.40 | -- | -- | -2.08 | -2.08 | 0.00 | 5.34 | 0.00 | -- | -- | 0.00 | -33.72 | -26.04 | -36.09 | -27.45 | -- | -- | -- | -- | -- | -- | 0.023 | -- | -- | -- | -12.36 | -- | -- | -- |
Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.40bn | 88.00 | -- | 3.33 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Akero Therapeutics Inc | 0.00 | -151.76m | 1.42bn | 55.00 | -- | 2.17 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
Morphic Holding Inc | 521.00k | -152.10m | 1.43bn | 121.00 | -- | 2.03 | -- | 2,737.16 | -3.49 | -3.49 | 0.0119 | 14.01 | 0.001 | -- | 2.29 | 4,305.79 | -27.88 | -22.69 | -28.99 | -24.99 | -- | -- | -29,192.90 | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
ADMA Biologics Inc | 258.22m | -28.24m | 1.44bn | 624.00 | -- | 10.37 | -- | 5.57 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Ardelyx Inc | 124.46m | -66.07m | 1.51bn | 267.00 | -- | 9.07 | -- | 12.17 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Dec 2023 | 7.37m | 9.68% |
Suvretta Capital Management LLCas of 31 Dec 2023 | 6.95m | 9.12% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.98m | 7.86% |
EcoR1 Capital, LLCas of 31 Dec 2023 | 5.81m | 7.63% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.94m | 5.17% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 2.98m | 3.91% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.92m | 3.84% |
Holocene Advisors, LPas of 31 Dec 2023 | 2.44m | 3.20% |
Armistice Capital LLCas of 31 Dec 2023 | 2.22m | 2.92% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.00m | 2.63% |